Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics

References

• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14. doi:10.4161/19420862.2015.989042.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417. doi:10.1038/clpt.2011.343.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5:621–623. doi:10.4161/mabs.25864.
   PubMed Web of Science ®Google Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435. doi:10.1007/s10067-013-2336-x.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol & Therapeut. 2014;40:620–628. doi:10.1111/apt.12869.
   Google Scholar
• Cohen ES, Dobson CL, Kack H, Wang B, Sims DA, Lloyd CO,  England E, Rees DG, Guo H, Karagiannis SN, et al. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014;6:756–764. doi:10.4161/mabs.28394.
   PubMedGoogle Scholar
• Chin SE, Ferraro F, Groves M, Liang M, Vaughan TJ, Dobson CL. Isolation of high affinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses. J Immunol Methods. 2015;416:49–58.
   Google Scholar
• Tornetta M, Fisher D, O’Neil K, Geng D, Schantz A, Brigham-Burke M, Lombardo D, Fink D, Knight D, Sweet R, et al. Isolation of human anti-idiotypic antibodies by phage display for clinical immune response assays. J Immunol Methods. 2007;328:34–44. doi:10.1016/j.jim.2007.08.008.
   PubMed Web of Science ®Google Scholar
• Hentrich C, Ylera F, Frisch C, Ten Haaf A, Knappik A. Chapter 3 – Monoclonal antibody generation by phage display: history, state-of-the-art, and future. In: Vashist SK, Luong JHT, editors. Handbook of immunoassay technologies. London: Academic Press; 2018:47–80.
   Google Scholar
• Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum Antibodies. 2009;18:47–73. doi:10.3233/HAB-2009-0206.
   PubMedGoogle Scholar
• Bourdage JS, Lee TN, Taylor JM, Willey MB, Brandt JT, Konrad RJ. Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies. J Pharm Biomed Anal. 2005;39:685–690. doi:10.1016/j.jpba.2005.03.037.
   PubMed Web of Science ®Google Scholar
• Verch T, Chilewski S, Bouaraphan S, Yarovoi H, Yin KC, Chen D, Washabaugh MW. Pharmacokinetic immunoassay methods in the presence of soluble target. J Immunol Methods. 2010;361:75–81. doi:10.1016/j.jim.2010.07.014.
   PubMed Web of Science ®Google Scholar
• Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis. 2010;2:1125–1140. doi:10.4155/bio.10.64.
   PubMed Web of Science ®Google Scholar
• Mayer AP, Hottenstein CS. Ligand-Binding assay development: what do you want to measure versus what you are measuring? Aaps J. 2016;18:287–289. doi:10.1208/s12248-015-9855-0.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu JF, Kamerud J, Ahene A, Myler H, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. Aaps J. 2011;13:99–110. doi:10.1208/s12248-011-9251-3.
   PubMed Web of Science ®Google Scholar
• Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M,  Norenberg S, Stark Y, Kolln J, Popp A, et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol. 2011;413:261–278. doi:10.1016/j.jmb.2011.08.012.
   PubMed Web of Science ®Google Scholar
• Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296:57–86. doi:10.1006/jmbi.1999.3444.
   PubMed Web of Science ®Google Scholar
• Virnekas B, Ge L, Pluckthun A, Schneider KC, Wellnhofer G, Moroney SE. Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res. 1994;22:5600–5607.
   PubMed Web of Science ®Google Scholar
• Steidl S, Ratsch O, Brocks B, Durr M, Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol. 2008;46:135–144. doi:10.1016/j.molimm.2008.07.013.
   PubMed Web of Science ®Google Scholar
• Pack P, Pluckthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 1992;31:1579–1584.
   PubMed Web of Science ®Google Scholar
• Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Pluckthun A, Pack P. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunology. (Baltimore, Md: 1950). 1996;157:2989–2997.
   PubMed Web of Science ®Google Scholar
• Amarasekera M. Immunoglobulin E in health and disease. Asia Pac Allergy. 2011;1:12–15. doi:10.5415/apallergy.2011.1.1.12.
   PubMedGoogle Scholar
• Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A. The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: case studies. MAbs. 2012;4:623–631. doi:10.4161/mabs.20814.
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–1264. doi:10.1038/nbt1344.
   PubMed Web of Science ®Google Scholar
• Ito R, Gon Y, Nunomura S, Atsuta R, Harada N, Hattori T, Maruoka S, Okayama Y, Ra C, Hashimoto S. Development of assay for determining free IgE levels in serum from patients treated with omalizumab. Allergol International: Official Journal Jpn Soc Allergol. 2014;63(Suppl 1):37–47. doi:10.2332/allergolint.13-OA-0643.
   PubMed Web of Science ®Google Scholar
• Talbot JJ, Calamba D, Pai M, Ma M, Thway TM. Measurement of free versus total therapeutic monoclonal antibody in pharmacokinetic assessment is modulated by affinity, incubation time, and bioanalytical platform. Aaps J. 2015;17:1446–1454. doi:10.1208/s12248-015-9807-8.
   PubMed Web of Science ®Google Scholar
• Lowe J, Wakshull E, Shek T, Chuntharapai A, Elliott R, Rusit J, Maia M. Development and validation of a novel semi-homogenous clinical assay for quantitation of ranibizumab in human serum. J Immunol Methods. 2018;461:44–52. DOI:10.1016/j.jim.2018.05.007
   Web of Science ®Google Scholar
• Krayukhina E, Noda M, Ishii K, Maruno T, Wakabayashi H, Tada M, Suzuki T, Ishii-Watabe A, Kato M, Uchiyama S. Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments. MAbs. 2017;9:664–679. doi:10.1080/19420862.2017.1297909.
   PubMed Web of Science ®Google Scholar
• Ylera F, Harth S, Waldherr D, Frisch C, Knappik A. Off-rate screening for selection of high-affinity anti-drug antibodies. Anal Biochem. 2013;441:208–213. doi:10.1016/j.ab.2013.07.025.
   PubMed Web of Science ®Google Scholar
• Jarutat T, Frisch C, Nickels C, Merz H, Knappik A. Isolation and comparative characterization of Ki-67 equivalent antibodies from the HuCAL phage display library. Biol Chem. 2006;387:995–1003. doi:10.1515/BC.2006.123.
   PubMed Web of Science ®Google Scholar
• Whiteaker JR, Zhao L, Frisch C, Ylera F, Harth S, Knappik A, Paulovich AG. High-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays. J Proteome Res. 2014;13:2187–2196. doi:10.1021/pr4009404.
   PubMed Web of Science ®Google Scholar
• Prassler J, Steidl S, Urlinger S. In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. Immunotherapy. 2009;1:571–583. doi:10.2217/imt.09.23.
   PubMed Web of Science ®Google Scholar
• Dunn C, O’Dowd A, Randall RE. Fine mapping of the binding sites of monoclonal antibodies raised against the Pk tag. J Immunol Methods. 1999;224:141–150.
   PubMed Web of Science ®Google Scholar
• Schmidt TG, Batz L, Bonet L, Carl U, Holzapfel G, Kiem K, Matulewicz K, Niermeier D, Schuchardt I, Stanar K. Development of the Twin-Strep-tag(R) and its application for purification of recombinant proteins from cell culture supernatants. Protein Expr Purif. 2013;92:54–61. doi:10.1016/j.pep.2013.08.021.
   PubMed Web of Science ®Google Scholar
• Knappik A, Brundiers R. Recombinant antibody expression and purification. In: J.M. W, editor. The protein protocols handbook. Totowa (NJ): Humana Press; 2009. p. 14.
   Google Scholar
• Ostendorp R, Frisch C, Urban M. Generation, engineering and production of human antibodies using Hucal®. In: Subramanian G, editor. Antibodies. New York: Springer US; 2004. p. 13–52.
   Google Scholar
• Cho MS, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci. 2002;9:631–638. doi:10.1159/000067294.
   PubMed Web of Science ®Google Scholar
• Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, Malka M, Chumakov I, Kotzer S, Resnitzky D. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem. 2003;278:38194–38205. doi:10.1074/jbc.M303164200.
   PubMed Web of Science ®Google Scholar